Lonapegsomatropin

What is Lonapegsomatropin?

Lonapegsomatropin (full nonproprietary name lonapegsomatropin-tcgd, marketed as SKYTROFA) is a once-weekly prodrug of human growth hormone developed by Ascendis Pharma. The FDA approved it on 25 August 2021 for pediatric growth hormone deficiency, and on 25 July 2025 expanded the label to adults with growth hormone deficiency — so it now covers both ends of the GHD spectrum. The engineering problem it addresses is adherence rather than potency. Recombinant human growth hormone has been available since 1985 and works well, but it has a short half-life and is therefore injected daily, typically for years and usually into a child by a parent. Real-world adherence to daily paediatric GH is mediocre, and missed doses translate directly into lost height. A weekly option is not a pharmacological improvement on somatropin so much as a practical one — and the practical one is what determines outcomes in a therapy whose success depends on years of consistent administration. Lonapegsomatropin uses the TransCon ('transient conjugation') platform: unmodified somatropin is attached to an inert methoxy-polyethylene-glycol carrier through a linker engineered to hydrolyse at a predictable rate. While conjugated, the molecule is inactive and protected from clearance; the linker then slowly releases free, structurally unmodified growth hormone across the week. This distinguishes it from the other two approved weekly GH products — somatrogon is a fusion protein with three copies of the C-terminal peptide of hCG attached, and somapacitan is an albumin-binding analog — both of which are modified proteins. Lonapegsomatropin delivers native somatropin; what is modified is only its availability. The pivotal pediatric trial, heiGHt, did something unusual for a convenience-driven reformulation: in 161 treatment-naïve prepubertal children over 52 weeks it produced an annualized height velocity of 11.2 cm/year versus 10.3 on daily somatropin (p=0.009), clearing not only its non-inferiority margin but a superiority test as well.

What Lonapegsomatropin Is Investigated For

Lonapegsomatropin has two approved indications and solid Phase 3 evidence behind both. In pediatric growth hormone deficiency the pivotal trial is heiGHt (NCT02781727), a 52-week open-label, active-controlled Phase 3 study across 73 sites in 15 countries that randomized 161 treatment-naïve prepubertal children 2:1 to weekly lonapegsomatropin 0.24 mg/kg or daily somatropin. Annualized height velocity was 11.2 cm/year versus 10.3 (p=0.009) and height standard-deviation score improved +1.10 versus +0.96 (p=0.01) — the trial met non-inferiority and then cleared superiority, which is uncommon for a product whose main selling point is dosing frequency. fliGHt (NCT03305016) established safety and tolerability in 146 children switching from daily somatropin, with annualized height velocity of 8.7 cm/year. The open-label extension enliGHten (NCT03344458) followed 298 children, with height SDS improving from −2.89 to −1.37 by week 104 and final results showing sustained height gains for up to six years — the longest continuous dataset for any weekly GH product. Adult GHD was added in July 2025 on the strength of foresiGHt (NCT04615273), a 38-week Phase 3 trial across 116 centres that randomized 259 adults 1:1:1 to weekly lonapegsomatropin, placebo, or daily somatropin. The primary endpoint was body composition rather than growth, which is the right endpoint in adults: trunk percent fat fell 1.68% on lonapegsomatropin versus rising 0.37% on placebo, a least-squares mean difference of −2.04% (p<0.001), with lean mass increasing 1.60 kg versus falling 0.11 kg (p<0.0001). The caveats are mostly class-level rather than product-specific, and they are substantial. Growth hormone carries a long list of contraindications and fourteen separate Warnings and Precautions, including increased mortality when given during acute critical illness, neoplasm risk in childhood cancer survivors who received cranial irradiation, glucose intolerance and new-onset diabetes, intracranial hypertension, and sudden death in children with Prader-Willi syndrome who are severely obese or have upper-airway obstruction. Case reports document severe transient hyperglycemia and even diabetic ketoacidosis in children without pre-existing diabetes on long-acting GH. A network meta-analysis comparing the three weekly products found broadly similar efficacy, so cross-product superiority claims are not supportable. And the weekly-versus-daily adherence advantage, while intuitively compelling, has not been demonstrated to produce better final adult height in a controlled comparison.

History & Discovery

Growth hormone therapy has one of the more consequential histories in endocrinology. From the late 1950s until 1985, children with growth hormone deficiency were treated with GH extracted from human cadaver pituitaries — a supply-limited product that was withdrawn after recipients developed Creutzfeldt-Jakob disease from prion-contaminated batches. Recombinant human growth hormone, produced in E. coli, replaced it in 1985 and both eliminated the contamination risk and removed the supply ceiling. It also fixed the dosing schedule at once daily, because recombinant somatropin has a short circulating half-life. Daily injection for years, usually administered to a child by a parent, is where the clinical problem sat. Adherence to pediatric GH is mediocre in real-world cohorts, and unlike many chronic therapies the cost of missed doses is not abstract — growth is time-limited, growth plates close, and height not gained during childhood cannot be recovered later. That created a clear rationale for weekly formulations, and by the 2020s three had reached approval using three distinct strategies: somatrogon (a fusion protein carrying three copies of the C-terminal peptide of hCG), somapacitan (an albumin-binding analog), and lonapegsomatropin. Ascendis Pharma's contribution came from its TransCon platform rather than from protein engineering. TransCon — 'transient conjugation' — attaches an unmodified parent drug to an inert carrier through a linker designed to hydrolyse at a predictable rate, so that the conjugate is pharmacologically silent and the parent molecule is released slowly and structurally unaltered. Applied to growth hormone, this produced a product that delivers native somatropin rather than a modified protein, with roughly a quarter of the administered mass being the hormone itself and the remainder carrier and linker. The clinical program was thorough and, unusually, went beyond non-inferiority. heiGHt (NCT02781727) randomized 161 treatment-naïve prepubertal children across 73 sites in 15 countries 2:1 to weekly lonapegsomatropin or daily somatropin for 52 weeks, and reported annualized height velocity of 11.2 versus 10.3 cm/year with p=0.009 — meeting superiority as well as non-inferiority (Thornton et al., JCEM 2021). fliGHt (NCT03305016) established that switching from daily somatropin was safe and well tolerated in 146 children (Maniatis et al., Horm Res Paediatr 2022). The open-label extension enliGHten (NCT03344458) rolled participants forward from both trials, reporting height SDS improvement from −2.89 to −1.37 by week 104 (Maniatis et al., JCEM 2022) and ultimately sustained height gains for up to six years (Maniatis et al., Horm Res Paediatr 2026) — the longest continuous dataset for any weekly GH product. The FDA approved SKYTROFA on 25 August 2021 under BLA 761177 for pediatric patients aged 1 year and older weighing at least 11.5 kg with growth failure due to inadequate endogenous growth hormone secretion. Adult growth hormone deficiency followed on 25 July 2025 on the strength of foresiGHt (NCT04615273), a 38-week Phase 3 trial in 259 adults across 116 centres that used body composition rather than growth as its primary endpoint and showed a 2.04% least-squares mean advantage in trunk percent fat over placebo alongside a 1.7 kg lean-mass difference (Biller et al., JCEM 2026). A Chinese Phase 3 trial supported regional registration (Ying et al., Horm Res Paediatr 2026), and real-world outcomes are being tracked through the INSIGHTS-GHT registry. Commercially SKYTROFA has been the steadier of Ascendis's endocrinology products rather than the breakout — €55 million in the second quarter of 2026, against €252 million for YORVIPATH in the same quarter. The weekly growth hormone market is genuinely contested between three approved products whose efficacy a 2024 network meta-analysis found broadly comparable, which puts competition onto device usability, titration convenience, and payer access rather than growth outcomes.

How It Works

Growth hormone is made by the pituitary gland and drives growth in children, mostly by telling the liver to release a second hormone called IGF-1 that acts on bone growth plates and muscle. Children who cannot make enough grow slowly and end up short; adults who cannot make enough tend to carry more fat around the trunk, lose lean mass, and feel worse. The standard treatment has been a daily injection of lab-made growth hormone since the mid-1980s — effective, but daily injections for years are hard to keep up, and missed doses cost height. Lonapegsomatropin attaches ordinary growth hormone to an inert carrier using a linker that slowly falls apart. After one weekly injection, the linker releases real, unaltered growth hormone bit by bit over the following seven days. One shot a week instead of seven, delivering the same molecule.

Human growth hormone is a 191-residue protein secreted in pulses by anterior pituitary somatotrophs under hypothalamic control — stimulated by growth hormone-releasing hormone and ghrelin, inhibited by somatostatin. It signals through the growth hormone receptor, a class I cytokine receptor that dimerises on ligand binding and activates JAK2, which phosphorylates STAT5 (principally STAT5b) for translocation to the nucleus, alongside MAPK and PI3K–Akt arms. The dominant growth-promoting output is indirect: hepatic GH receptor activation drives transcription of IGF-1, which circulates bound to IGFBP-3 and the acid-labile subunit and acts on growth-plate chondrocytes to drive clonal expansion and hypertrophy. Growth hormone also acts directly on chondrocytes, adipocytes (stimulating lipolysis), and skeletal muscle, and it has counter-regulatory metabolic effects — reduced insulin sensitivity and increased hepatic glucose output — which is why glucose intolerance is a class-level concern. Recombinant human growth hormone has been available since 1985 and has a short circulating half-life, which dictated once-daily subcutaneous dosing for four decades. Three strategies have since achieved weekly dosing, and they are genuinely different. Somatrogon is a fusion protein appending three copies of the C-terminal peptide of human chorionic gonadotropin to the GH sequence, slowing clearance. Somapacitan is a GH analog bearing an albumin-binding moiety, so the drug circulates reversibly bound to albumin. Lonapegsomatropin takes a prodrug approach instead: unmodified somatropin is conjugated to an inert methoxy-polyethylene-glycol carrier through a TransCon transient linker. In the conjugated state the molecule cannot engage the GH receptor and is shielded from proteolysis and renal clearance; the linker then undergoes predictable, pH- and temperature-dependent hydrolysis, liberating free somatropin — structurally identical to endogenous growth hormone — at a controlled rate across the dosing week. Approximately 25% of the administered mass is somatropin; the remainder is carrier and linker, which is why the mg doses are not directly comparable to daily somatropin mg doses. The practical consequence is that lonapegsomatropin produces sustained rather than pulsatile GH exposure. This is a genuine departure from physiology, since endogenous GH is secreted in nocturnal pulses, and it is a fair question whether continuous exposure has different long-term consequences than pulsatile — particularly for glucose metabolism and for IGF-1 dynamics. In practice IGF-1 is monitored with the sample drawn 4 to 5 days after a dose, standardising the measurement to a consistent point on the release curve. In adults, the therapeutic target shifts from linear growth to body composition and metabolic function, since the growth plates have closed. The foresiGHt trial accordingly used trunk percent fat as its primary endpoint, reporting a 1.68% reduction on lonapegsomatropin versus a 0.37% increase on placebo (least-squares mean difference −2.04%, p<0.001) with lean mass rising 1.60 kg versus falling 0.11 kg (p<0.0001) over 38 weeks — the expected signature of restored GH-driven lipolysis and anabolism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Lonapegsomatropin:

• 01Whether weekly dosing produces greater final adult height than daily somatropin through improved real-world adherence — the central practical claim for this drug class, and untested. heiGHt demonstrated a one-year height-velocity advantage in a trial setting where adherence is monitored in both arms, which is precisely the setting least able to reveal an adherence benefit.
• 02How the three approved weekly growth hormone products actually compare — the available network meta-analysis (de Fries Jensen et al., 2024) found somapacitan, somatrogon, and lonapegsomatropin broadly comparable, and no head-to-head trial exists. Product selection currently rests on device, titration convenience, and access.
• 03Whether sustained rather than pulsatile growth hormone exposure has different long-term consequences than the nocturnal-pulse physiology it replaces, particularly for glucose metabolism, IGF-1 dynamics, and any mitogenic risk over decades of childhood exposure.
• 04The denominator behind the glucose signal — case reports document severe transient hyperglycemia and diabetic ketoacidosis in children without pre-existing diabetes on long-acting growth hormone, but the incidence and the risk factors that identify vulnerable children are not established.
• 05Long-term neoplasm and second-neoplasm surveillance specific to long-acting formulations, since the exposure pattern differs from daily somatropin even at equivalent total dose. Meningioma risk in childhood cancer survivors who received cranial irradiation is a labeled warning built on daily-GH data.
• 06The significance of the laboratory shifts seen more often on lonapegsomatropin than on daily somatropin — elevated phosphate in 44% versus 30% and elevated alkaline phosphatase in 19% versus 9% — which have not been fully characterised clinically.
• 07Adult GHD outcomes beyond body composition — foresiGHt used trunk percent fat as its primary endpoint over 38 weeks. Whether replacement improves cardiovascular outcomes, fracture risk, or mortality in adult GHD remains the larger unanswered question for the indication as a whole, not just for this product.
• 08Use in growth failure indications other than GHD — Turner syndrome, small for gestational age, idiopathic short stature, chronic kidney disease, and Prader-Willi syndrome are approved indications for some daily somatropin products but not for lonapegsomatropin, and dedicated trials have not been reported.

Forms & Administration

SKYTROFA is supplied as single-dose dual-chamber prefilled cartridges in 14 strengths — 0.7, 1.4, 1.8, 2.1, 2.5, 3, 3.6, 4.3, 5.2, 6.3, 7.6, 9.1, 11, and 13.3 mg — used with a reusable auto-injector that mixes the lyophilised drug with diluent immediately before administration. Dosing is once weekly by subcutaneous injection. Pediatric dosing is 0.24 mg/kg of body weight per week, identical for treatment-naïve children and those switching from daily somatropin. Adult starting doses are set by age and oral estrogen status: 2.1 mg weekly for adults under 30 or on oral estrogen at any age, 1.4 mg weekly for adults aged 30 to 60 not on oral estrogen, and 0.7 mg weekly for adults over 60 not on oral estrogen, with monthly titration to the next cartridge strength guided by clinical response and IGF-1 measured 4 to 5 days after a dose. When switching from daily somatropin, the first weekly dose is given at least 8 hours after the final daily dose; when switching from another weekly growth hormone, at least 7 days after. A fundoscopic examination is recommended before initiation to exclude pre-existing papilledema. Injection sites should be rotated. Because roughly a quarter of the administered mass is somatropin and the rest is carrier and linker, milligram doses are not interchangeable with daily somatropin milligram doses. Initiation and monitoring belong with a pediatric or adult endocrinologist.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

SKYTROFA is approved only for growth hormone deficiency: children aged 1 and older weighing at least 11.5 kg with growth failure from inadequate endogenous GH secretion, and adults with confirmed GHD. Growth hormone has a long contraindication list including acute critical illness, active malignancy, and specific Prader-Willi presentations, plus fourteen labeled Warnings and Precautions. The figures above reproduce the FDA label for reference and are not prescribing guidance. Use outside diagnosed deficiency is unapproved, and growth hormone is prohibited at all times under WADA category S2.

Timeline of Effects

Common Questions

Who Lonapegsomatropin Is NOT For

Drug & Supplement Interactions

Growth hormone's interactions are largely endocrine and metabolic rather than pharmacokinetic in the CYP-competition sense, though one genuine hepatic-enzyme interaction exists. Glucocorticoids are the most clinically important interaction in both directions. Supraphysiological glucocorticoid doses inhibit the growth-promoting effect of growth hormone, so children on chronic corticosteroids may respond poorly and require dose adjustment of the steroid where possible. Conversely, growth hormone increases the conversion of cortisone and prednisone to their active metabolites via 11-beta-hydroxysteroid dehydrogenase type 1, and it can unmask previously undiagnosed central hypoadrenalism — patients on glucocorticoid replacement may need their dose increased when growth hormone is started. Oral estrogen requires a higher growth hormone dose to achieve the same IGF-1 response, because first-pass hepatic exposure blunts GH-stimulated IGF-1 generation. This is not a caution but a dosing rule built into the adult label, which specifies 2.1 mg weekly as the starting dose for adults on oral estrogen at any age versus 1.4 mg for adults aged 30 to 60 who are not. Transdermal estrogen does not carry the same effect. Women switching between oral and non-oral estrogen routes may need their growth hormone dose revisited. Insulin and oral antidiabetic agents commonly need adjustment upward, because growth hormone reduces insulin sensitivity and increases hepatic glucose output. This is the interaction most likely to cause a clinical problem in practice, and the published case reports of severe hyperglycemia and diabetic ketoacidosis on long-acting growth hormone underline why glucose monitoring should be active rather than routine. Thyroid hormone replacement often needs revisiting, since growth hormone increases peripheral conversion of T4 to T3 and can unmask central hypothyroidism. Growth hormone also induces cytochrome P450 activity, which can reduce serum concentrations of CYP450-metabolised drugs including some anticonvulsants, cyclosporine, and sex steroids — dose adjustment may be needed for narrow-therapeutic-index agents. All concomitant medications, over-the-counter products, and supplements should be disclosed to the prescribing endocrinologist, with particular attention to corticosteroids, thyroid replacement, estrogen preparations, and diabetes medications.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions